Related Experiment Video
Updated: Jun 6, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB): a new potential therapeutic target in
Józefa Dąbek1, Andrzej Kułach, Zbigniew Gąsior
1Department of Cardiology, Medical University of Silesia, Ziołowa 47, PL40-635 Katowice, Poland.
Abstract:
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a crucial transcription factor that participates in a number of physiological and pathological conditions, including immune response, apoptosis, carcinogenesis and inflammatory processes. It is involved in the rapid response to various stimuli such as viral and bacterial infections, shear stress, oxidant stress and a number of cytokines. In the pathology of atherosclerosis NF-κB is essential to the cross-talk between cytokines, adhesion molecules and growth factors, leading to atherosclerotic plaque formation, growth and eventual rupture. The intent of this paper is to gather and summarize information on the role of NF-κB in the pathology of atherosclerosis. Additionally, pharmacological intervention in the signaling of NF-κB is addressed along with the potential benefits and disadvantages of NF-κB modulating treatment.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Co-activators and Co-repressors